Invest in smarter healthcare
Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange (ASX:LDX).
World-Class Team
Point-of-care Products
Revenue-Generating Company
Global Commercial and Distribution Partnerships
Lumos Diagnostics Holdings Ltd
ASX:LDX · Lumos Diagnostics Holdings Ltd
A$0.11
+0.01 (+8.25%)As at 4:00 PM · 4 Sep 2026 · 20-minute delay
Market data
| Ticker | LDX |
| Last price | A$0.11 |
| Previous close | A$0.10 |
| Day high | A$0.11 |
| Day low | A$0.10 |
| 52 week high | A$0.33 |
| 52 week low | A$0.08 |
Trading
| Trading volume | 841.7K |
| Turnover | A$88.4K |
| VWAP (5d) | A$0.10 |
| Bid / Ask | N/A |
| Market cap | A$99.2M |
| Shares outstanding | N/A |
| P/E ratio | N/A |
Share price data is provided on a 20-minute delay and is sourced from external market data providers. For live data please consult your broker.
2026
01 Sep 2026
1:50pm
Section 708A Cleansing Statement
Cleansing Notice
01 Sep 2026
1:48pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
01 Sep 2026
1:04pm
Change of Director's Interest Notice - DW
Change of Director's Interest Notice
26 Aug 2026
10:06am
Appendix 4G and Corporate Governance Statement
Corporate Governance
Takeover - Appendix 4G
26 Aug 2026
9:44am
Market sensitive
FY26 Full Year Results Announcement
Preliminary Final Report
Periodic Reports - Other
26 Aug 2026
9:41am
FY26 Annual Report
Annual Report
Top 20 shareholders
Full Year Accounts
Full Year Audit Review
Full Year Directors' Statement
Full Year Directors' Report
26 Aug 2026
9:22am
Market sensitive
FY26 Appendix 4E
Preliminary Final Report
07 Aug 2026
11:02am
Lumos to Present at 20th Bioshares Biotech Summit
Company Presentation
04 Aug 2026
9:04am
Market sensitive
Lumos Receives FebriDx Order from PHASE Scientific
Progress Report
30 Jul 2026
9:38am
Lumos Secures Distribution for FebriDx in Romania
Progress Report
28 Jul 2026
12:42pm
Change of Director's Interest Notice - DW
Change of Director's Interest Notice
28 Jul 2026
9:40am
Section 708A Cleansing Statement
Cleansing Notice
28 Jul 2026
9:37am
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
27 Jul 2026
12:01pm
Investor Presentation
Company Presentation
Web Casts
27 Jul 2026
9:55am
Market sensitive
Quarterly Activities/Appendix 4C Cash Flow Report
Web Casts
Commitments Test Entity - Fourth Quarter Report
Commitments Test Entity - Fourth Quarter Activity Report
21 Jul 2026
12:08pm
Market sensitive
FebriDx Commercial Traction Across Priority US Accounts
Progress Report
20 Jul 2026
11:01am
Q4 FY26 Results Release Date and Webinar Invitation
Notification of Results/Reporting Date
20 Jul 2026
10:50am
Investor Information Sessions
Company Administration - Other
14 Jul 2026
1:06pm
Notification of cessation of securities - LDX
Appendix 3H (Notification of cessation of securities)
02 Jul 2026
2:27pm
Closure of A$5M Loan Facility with Major Shareholders
Debt Facility
29 Jun 2026
9:54am
Market sensitive
Lumos Receives Research & Development Tax Rebate
Periodic Reports - Other
25 Jun 2026
11:48am
Change of Director's Interest Notice - SL
Change of Director's Interest Notice
22 Jun 2026
12:12pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
19 Jun 2026
9:13am
Change of Director's Interest Notice - CR
Change of Director's Interest Notice
11 Jun 2026
9:58am
Investor Presentation - FebriDx US Commercial Update
Company Presentation
05 Jun 2026
2:51pm
Change of Director's Interest Notice - DW
Change of Director's Interest Notice
04 Jun 2026
11:23am
FebriDx US Commercial Update Webinar Invitation
Web Casts
20 May 2026
1:24pm
Section 708A Cleansing Statement
Cleansing Notice
20 May 2026
1:24pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
18 May 2026
11:42am
Market sensitive
FebriDx U.S. Rollout and Reimbursement Update - Amended
Progress Report
18 May 2026
9:49am
Market sensitive
FebriDx U.S. Rollout and Reimbursement Update
Progress Report
14 May 2026
9:37am
Market sensitive
FebriDx Paediatric Study Enrolment Milestone Achieved
Progress Report
07 May 2026
2:02pm
Lumos receives US$0.5m CLIA waiver milestone payment
Periodic Reports - Other
01 May 2026
11:16am
Change of Director's Interest Notice - CR
Change of Director's Interest Notice
01 May 2026
11:16am
Change of Director's Interest Notice - SL
Change of Director's Interest Notice
01 May 2026
11:11am
Notification regarding unquoted securities - LDX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
01 May 2026
11:10am
Notification regarding unquoted securities - LDX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
01 May 2026
11:08am
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
01 May 2026
11:04am
Results of Share Purchase Plan
Security Purchase Plan
30 Apr 2026
4:23pm
Change of Director's Interest Notice - SL
Change of Director's Interest Notice
21 Apr 2026
10:32am
Q3 FY26 Results Investor Presentation
Company Presentation
Commitments Test Entity - Third Quarter Report
20 Apr 2026
9:49am
Market sensitive
Quarterly Activities/Appendix 4C Cash Flow Report
Commitments Test Entity - Third Quarter Report
Commitments Test Entity - Third Quarter Activity Report
16 Apr 2026
9:33am
Notification of cessation of securities - LDX
Appendix 3H (Notification of cessation of securities)
15 Apr 2026
4:26pm
Lumos Q3 FY26 Results Webinar Invitation
Security Purchase Plan
Web Casts
Notification of Results/Reporting Date
14 Apr 2026
2:35pm
Lumos expands WellStreet Urgent Care locations
Progress Report
14 Apr 2026
10:14am
Change in substantial holding from RYD
Change in substantial holding
14 Apr 2026
9:13am
Lumos receives US$5m FebriDx milestone payment from PHASE
Progress Report
10 Apr 2026
5:31pm
Market sensitive
Response to ASX Aware Letter
Response to ASX Query
10 Apr 2026
9:32am
Target Market Determination
Other
10 Apr 2026
9:31am
Market sensitive
Prospectus
Disclosure Document
10 Apr 2026
9:30am
SPP - Letter to Eligible Shareholders
Security Purchase Plan
Letter to Shareholders
09 Apr 2026
12:10pm
Section 708A Cleansing Statement
Cleansing Notice
09 Apr 2026
12:10pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
09 Apr 2026
12:06pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
09 Apr 2026
12:05pm
Section 708A Cleansing Statement
Cleansing Notice
08 Apr 2026
9:45am
Market sensitive
Lumos secures new contract manufacturing agreement
Progress Report
02 Apr 2026
12:01pm
Section 708A Cleansing Statement
Cleansing Notice
02 Apr 2026
12:00pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
01 Apr 2026
10:47am
Market sensitive
Lumos receives largest FebriDx order to date
Progress Report
27 Mar 2026
4:33pm
Investor Briefing Invitation
Web Casts
27 Mar 2026
10:13am
Market sensitive
Investor Presentation
Company Presentation
Placement
Security Purchase Plan
27 Mar 2026
10:08am
Market sensitive
US FDA Grants CLIA Waiver for FebriDx
Trading Halt Lifted
Progress Report
27 Mar 2026
10:08am
Proposed issue of securities - LDX
Appendix 3B
27 Mar 2026
10:08am
Market sensitive
Lumos completes $20m placement and launches SPP
Placement
Security Purchase Plan
25 Mar 2026
9:21am
Market sensitive
Trading Halt
Trading Halt
05 Mar 2026
9:34am
Section 708A Cleansing Statement
Cleansing Notice
05 Mar 2026
9:32am
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
03 Mar 2026
10:31am
1H FY26 Results Investor Presentation
Half Yearly Report
Company Presentation
27 Feb 2026
9:49am
Market sensitive
Lumos Delivers Several Pivotal Milestones in 1H FY26
Half Yearly Report
Web Casts
27 Feb 2026
9:47am
Market sensitive
Appendix 4D and Half Year Report
Half Yearly Report
Half Year Audit Review
Half Year Directors' Statement
Half Year Accounts
Half Year Directors' Report
23 Feb 2026
9:45am
Market sensitive
Lumos Completes Enrolment Milestone for Paediatric Study
Progress Report
06 Feb 2026
9:06am
Section 708A Cleansing Statement
Cleansing Notice
06 Feb 2026
9:03am
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
03 Feb 2026
9:27am
Q2 FY26 Results Investor Presentation
Company Presentation
Commitments Test Entity - Second Quarter Activity Report
29 Jan 2026
2:22pm
Market sensitive
Quarterly Activities/Appendix 4C Cash Flow Report
Commitments Test Entity - Second Quarter Report
Commitments Test Entity - Second Quarter Activity Report
19 Jan 2026
10:48am
Lumos secures follow on contract with Aptatek
Progress Report
09 Jan 2026
5:01pm
Section 708A Cleansing Statement
Cleansing Notice
09 Jan 2026
4:58pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
07 Jan 2026
12:20pm
Investor Webinar Invitation-Reducing Diagnostic Uncertainty
Web Casts
2025
18 Dec 2025
12:07pm
Lumos Secures Distribution for FebriDx in Baltic Region
Progress Report
21 Nov 2025
1:22pm
Section 708A Cleansing Statement
Cleansing Notice
21 Nov 2025
1:20pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
21 Nov 2025
1:17pm
Market sensitive
Lumos Secures 100% US Medicare Reimbursement for FebriDx
Progress Report
20 Nov 2025
8:30am
Lumos Enters Strategic Collaboration with AcuityMD
Progress Report
12 Nov 2025
3:29pm
Notification regarding unquoted securities - LDX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
31 Oct 2025
4:34pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
31 Oct 2025
4:31pm
Change of Director's Interest Notice - DW
Change of Director's Interest Notice
31 Oct 2025
4:26pm
Notification regarding unquoted securities - LDX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
28 Oct 2025
4:32pm
New Constitution
Constitution
24 Oct 2025
12:49pm
Results of Annual General Meeting
Results of Meeting
24 Oct 2025
8:56am
2025 AGM Presentation
Company Presentation
Chairman's Address to Shareholders
24 Oct 2025
8:51am
AGM Chair Address
Chairman's Address to Shareholders
23 Oct 2025
8:34am
Market sensitive
Quarterly Activities/Appendix 4C Cash Flow Report
Notice of Meeting - Other
Commitments Test Entity - First Quarter Report
Commitments Test Entity - First Quarter Activity Report
22 Oct 2025
9:35am
Lumos Commences FebriDx CLIA Waiver Pediatric Study
Progress Report
16 Oct 2025
9:34am
Lumos Agreement with WellStreet Urgent Care for FebriDx
Progress Report
13 Oct 2025
10:36am
Addendum to Notice of Annual General Meeting
Notice of Meeting - Other
24 Sep 2025
3:31pm
FebriDx UK Data Shows Reduced Antibiotic Use & Cost Savings
Progress Report
24 Sep 2025
11:25am
ASX SMIDcaps 2025 Conference Presentation
Company Presentation
19 Sep 2025
3:58pm
Notice of Annual General Meeting and Proxy Form
Notice of Annual General Meeting
Proxy Form
15 Sep 2025
3:25pm
Section 708A Cleansing Statement
Cleansing Notice
15 Sep 2025
3:23pm
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
11 Sep 2025
9:52am
Section 708A Cleansing Statement
Cleansing Notice
11 Sep 2025
9:50am
Application for quotation of securities - LDX
Appendix 2A (Application for Quotation of Securities
09 Sep 2025
2:53pm
Lumos Signs Second ANZ FebriDx Distribution Agreement
Progress Report
09 Sep 2025
2:10pm
Lumos Completes A$5.0 million Loan Facility
Debt Facility
08 Sep 2025
4:25pm
Notification regarding unquoted securities - LDX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Showing 1–10 of 106 announcements
| 24/07/2026 | Foster Stockbroking | Second major customer comes on board | 342KB (6 pages) |
| 01/04/2026 | Foster Stockbroking | A wider net is cast | 316KB (9 pages) |
| 10/02/2026 | MST Access | CLIA Waiver Decision Approaching | 1.5MB (10 pages) |
| 05/11/2025 | Foster Stockbroking | FebriDx to hit fever pitch | 508KB (21 pages) |
| 19/09/2025 | Sandstone Insights | FebriDx CLIA waiver submission | 350KB (3 pages) |
| 19/08/2025 | MST Access | FebriDx CLIA waiver submission | 1.1MB (10 pages) |
| 07/05/2025 | MST Access | More Medicare Reimbursement Coverage Secured for FebriDx | 5.5MB (42 pages) |
| 28/03/2025 | MST Access | Transforming Point-of-Care Medicine with Rapid Diagnostics | 5.5mb (42 pages) |
Charters
| Board Charter | ||
| Audit and Risk Committee Charter | ||
| Remuneration and Nomination Committee Charter |
Policies
Constitution
| Constitution of Lumos Diagnostics Holdings Limited |
“Lumos represents a compelling investment opportunity. We have secured strategic partnerships with leading healthcare companies. We are expanding our commercial services division across human health, animal health, food testing and molecular testing. We have secured key FDA clearances for our Point-of-care products. Collectively, our Company has firm foundations for considerable revenue growth.”